Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XAAET
ADC Name
WO2013055987A1 xCD22-103
Synonyms
WO2013055987A1 xCD22-103
   Click to Show/Hide
Organization
ADC Therapeutics SA; Genentech, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Diffuse large B-cell lymphoma [ICD11:2A81]
Investigative
Drug-to-Antibody Ratio
1.8
Structure
Antibody Name
Anti-CD22 mAb xCD22
  Antibody Info 
Antigen Name
B-cell receptor CD22 (CD22)
  Antigen Info 
Payload Name
SG2000
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
WO2013055987A1_xCD22-103 linker
General Information of The Activity Data Related to This ADC
Obtained from the Model Organism Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI) 
≈ 81.1
%
Breast cancer model MMTV-HER2 Fo5
Full List of Activity Data of This Antibody-drug Conjugate
Obtained from the Model Organism Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 81.10% (Day 11) High HER2 expression (HER2 +++)
Method Description
Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. When tumor sreached desired volumes, the tumor-bearing mice were randomized and given a single dose by IV 10 mg/kg injection of the ADC.
In Vivo Model Breast cancer model MMTV-HER2 Fo5
References
Ref 1 Pyrrolobenzodiazepines and conjugates thereof; 2013-04-18.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.